NSE ScannerChemicals · Chemicals: Specialty · NSE: TRUALT · data 2026-10-30
Trualt Bioenergy Limited
In plain words
Price: 33.7% below its 52-week high of ₹542.
Delivery: 53.6% of traded shares were kept for delivery over the last 10 sessions, against 55.4% over the last 60.
Latest results: a net profit of ₹57 cr for the quarter ended Jun 2026 (+1108.2% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,747 cr |
| Net profit (last 12 months) | ₹221 cr |
| Sales growth, 3 years (yearly) | 29.9% |
| Profit growth, 3 years (yearly) | 39.3% |
Latest results in brief (Q1 FY27)
TRUALT Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹626.88 crore, up 106.3% YoY and up 5.3% QoQ.
Net profit was ₹57.15 crore, up 1,108.2% YoY and down 4.6% QoQ.
Operating margin was 21.2% (13.7% a year ago).
EPS was ₹6.67, up 1,112.7% YoY and down 4.6% QoQ.
TRUALT के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹626.88 करोड़; पिछले साल की तुलना में 106.3% की बढ़त, पिछली तिमाही की तुलना में 5.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹57.15 करोड़; पिछले साल की तुलना में 1,108.2% की बढ़त, पिछली तिमाही की तुलना में 4.6% की गिरावट।
ऑपरेटिंग मार्जिन: 21.2% (एक साल पहले 13.7%)।
EPS: ₹6.67; पिछले साल की तुलना में 1,112.7% की बढ़त, पिछली तिमाही की तुलना में 4.6% की गिरावट।
TRUALTના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹626.88 કરોડ; ગયા વર્ષની સરખામણીએ 106.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 5.3% વધારો.
ચોખ્ખો નફો: ₹57.15 કરોડ; ગયા વર્ષની સરખામણીએ 1,108.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 21.2% (એક વર્ષ પહેલાં 13.7%).
EPS: ₹6.67; ગયા વર્ષની સરખામણીએ 1,112.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
22/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 50.8% over the last 20 sessions vs 57.7% in the 40 before (0.88x); shares delivered per day 0.77x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 17/20: Net +₹19.88 cr bought in bulk/block deals over 90 days (1.89x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Deal
- 25 Sept 26Results Q4 FY26 results: net profit ₹59.9 cr +6.8% next session
- 23 Sept 26Deal Bulk deal: SIDDHISURI FINVEST PRIVATE LIMITED bought ₹19.88 cr +3.5% next session
- 28 Jul 26Results Q1 FY27 results: profit +1108.2% YoY +2.1% next session
- 3 Feb 26Results Q3 FY26 results: net profit ₹69.3 cr -0.1% next session
- 12 Nov 25Results Q2 FY26 results: net profit −₹37.9 cr +2.9% next session
- 21 Oct 25Results Q1 FY26 results: net profit ₹4.7 cr +0.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹627 cr | ₹57 cr | +1108.2% | 21.2% | 6.67 |
| Mar 2026 | ₹596 cr | ₹60 cr | — | 19.9% | 6.99 |
| Dec 2025 | ₹713 cr | ₹69 cr | — | 18.8% | 8.07 |
| Sept 2025 | ₹115 cr | ₹-38 cr | — | -4.0% | -5.37 |
Common questions
What was Trualt Bioenergy Limited's latest quarterly profit?
Trualt Bioenergy Limited reported a net profit of ₹57 cr for the quarter ended Jun 2026 (+1108.2% on the same quarter a year earlier), on revenue of ₹627 cr.
Is Trualt Bioenergy Limited debt-free?
Its latest reported debt-to-equity ratio is 1.09, meaning borrowings are larger than shareholders' equity.
What is Trualt Bioenergy Limited's P/E ratio?
About 14, based on the last 12 months' earnings and a price of ₹359.6 (data 2026-10-30).
What is the 52-week high and low of Trualt Bioenergy Limited?
The 52-week high is ₹542 and the 52-week low is ₹310.2.
Similar companies
Tatva Chintan Pharma Chem Limited (TATVA) · Grauer & Weil India Ltd. (GRAUWEIL) · Kiri Industries Limited (KIRIINDUS) · Styrenix Performance Materials Ltd (STYRENIX) · Polyplex Corporation Limited (POLYPLEX)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open TRUALT in NSE Scanner →